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Abstract
Background: Efficacy of oral pre-exposure prophylaxis (PrEP) in prevention of HIV acquisition has been evaluated
using a daily regimen. However, adherence to long term daily medication is rarely perfect. Intermittent regimen may
be a feasible alternative. Preclinical studies have demonstrated effectiveness of intermittent PrEP in SHIV prevention
among animals. However, little is known about intermittent PrEP regimens.
Design: Seventy two HIV-uninfected volunteers in HIV serodiscordant couple relationships in Uganda were randomly
assigned to receive daily oral Tenofovir/Emtricitabine (TDF/FTC-Truvada) or placebo, or intermittent (Monday, Friday
and within 2 hours after sex, not to exceed one dose per day) oral TDF/FTC or placebo in a 2:1:2:1 ratio. Volunteers
and study staff were blinded to drug assignment, but not to regimen assignment.
Methods: Volunteers were followed for 4 months after randomization, with monthly clinical and laboratory safety
assessments and comprehensive HIV risk reduction services. Adherence was monitored using medication event
monitoring system (MEMS) and self-report. Sexual activity data were collected via daily short text message (SMS)
and self-report. HIV-specific immune responses were assessed by IFN-γ ELISPOT.
Results: Both daily and intermittent oral TDF/FTC regimens were well tolerated. Median MEMS adherence rates
were 98% (IQR: 93-100) for daily PrEP regimen, 91% (IQR: 73-97) for fixed intermittent dosing and 45% (IQR: 20-63)
for post-coital dosing. SMS response rate was 74%, but increased to 80% after excluding server outages; results
may have been affected by the novelty of this measure. The majority of volunteers expressed willingness with no
particular preference for either regimen.
Conclusions: Both daily and intermittent oral PrEP dosing regimens were safe. Adherence was high for daily and
fixed intermittent dosing; post-coital dosing was associated with poor adherence. Fixed intermittent PrEP regimens
may be feasible especially if a minimum effective drug concentration correlating with HIV prevention can be achieved
with this dosing.
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Introduction
Most adult HIV infections in Africa are due to heterosexual
transmission [1], and being in a stable HIV discordant sexual
relationship  is  associated  with  a  10-fold  higher  risk  of  HIV
transmission  than  being  in  a  concordant  HIV-negative
relationship  [2,3].  HIV-uninfected  individuals  in  discordant
couple  relationships  are  therefore  among  the  most  at  risk
populations (MARPs). HIV serodiscordant couples enrolled in
an  HIV  vaccine  feasibility  study  in  Masaka,  Uganda,  had  an
HIV incidence rate of 4.3 and 4.4 per 100 person years (PY) in
men and women respectively [4].
At  the  peak  of  the  HIV  epidemic,  Uganda  adopted  the
promotion and dissemination of several prevention strategies to
control HIV transmission including abstinence, being faithful to
one’s  partner,  reducing  the  number  of  sexual  partners,
treatment of sexually transmitted infections (STI), HIV voluntary
counseling and testing (plus sharing of results with partners)
and  consistent  and  correct  use  of  condoms  [5].  These
strategies helped to reduce HIV prevalence [6]; however, they
have  limitations.  HIV  prevention  programs  that  focus  on
reducing the number of sexual partners, use of condoms during
casual sex and increased fidelity among married partners are
not  likely  to  directly  decrease  the  risk  of  HIV  transmission
among  persons  already  living  in  HIV  serodiscordant
relationships [3]. Therefore, research into new approaches to
HIV prevention particularly in HIV discordant couples remains
critical.
Recently,  several  trials  of  antiretroviral  pre-exposure
prophylaxis have shown major reductions in HIV acquisition. In
the  Pre-exposure  Prophylaxis  Initiative  (iPrEx)  study  -  a
randomized  multinational  clinical  trial  among  men  who  have
sex with men (MSM) - daily fixed dose combination regimen of
tenofovir disoproxil fumarate combined with emtricitabine (TDF/
FTC),  reduced  HIV  acquisition  by  44%  overall  [7].  Efficacy
correlated with adherence and detectable drug levels. Pill use
on  90%  or  more  of  days  was  associated  with  73%  efficacy,
while detectable drug levels were associated with 92% efficacy.
Subsequent  pharmacokinetic  modeling  of  the  iPrEx  data
suggest  that  7  days  per  week  dosing  could  achieve  99%
efficacy  in  prevention  of  HIV  infection  among  MSM,  while  4
days per week could still lower risk by 96% [8]. In the TDF2
study  –  a  randomized  trial  conducted  in  Botswana  among
young HIV-uninfected men and women - daily use of TDF/FTC
reduced HIV acquisition by 62% [9]. In the Partners PrEP trial –
a randomized multinational trial in HIV discordant couples in
Kenya  and  Uganda  -  daily  PrEP  of  either  TDF  alone  or
combined as TDF/FTC reduced the risk of HIV acquisition by
67-75%  [10].  Having  detectable  plasma  tenofovir  levels  was
associated with 86 and 90% reduction in HIV acquisition, for
the TDF and TDF/FTC groups respectively [11]. Interestingly,
two other randomized PrEP trials in at-risk women failed to find
a reduction in risk of HIV infection in the treatment group. The
FEM-PrEP trial of oral TDF/FTC in at-risk African women was
halted early due a likelihood of being unable to demonstrate
difference in HIV seroconversion based on interim data safety
monitoring board determination, as was the case for oral and
vaginal  tenofovir  arms  of  the  VOICE  study  [12,13].  The
explanations  for  these  contradictory  results  are  not  fully
understood;  however,  low  adherence  appeared  to  play  an
important role. In the FEM-PrEP trial, adherence by self-report
and pill counts were high, but plasma drug levels revealed that
only 15-26% of samples from HIV seroconverters actually had
tenofovir  detected,  as  well  as  only  26-38%  of  non-
seroconverting  controls  [14].  Thus,  study  medication
adherence  was  too  low  to  assess  its  protective  effect  in  the
trial. In 2012, the US Food and Drug Administration approved
daily Truvada for HIV prevention in individuals at high risk of
sexual HIV infection [15].
The above trials all included daily oral regimens which may
be  challenging  as  a  population-level  HIV  prevention  method.
Daily PrEP may be limited by adherence challenges, as well as
acceptability, toxicity and cost concerns, although most of the
blinded large efficacy trials have shown it to be acceptable and
safe.  An  intermittent  dosing  regimen  may  be  an  alternative
strategy  if  able  to  achieve  adequate  drug  levels  required  for
HIV prevention. The biological characteristics of TDF and FTC
favour usage of an intermittent PrEP regimen. Both TDF and
FTC are phosphorylated to active forms that have long half-
lives  in  plasma  and  peripheral  blood  mononuclear  cells
(PBMCs) of ≥60 and 39 hours respectively [16,17]. Additionally,
in  studies  using  macaques  as  animal  models,  intermittent
PrEP, given 2 hours before and 24 hours after each weekly
virus  challenge,  protected  animals  against  SHIV  as  well  as
daily PrEP [18].
In this randomized, double-blind study, we evaluated safety,
acceptability  and  adherence  to  an  intermittent  PrEP  regimen
with TDF/FTC compared to a daily regimen among men and
women living in HIV serodiscordant couple relationships. The
intermittent  regimen  was  defined  as  twice  weekly  dosing
(Mondays and Fridays) plus a coitally-dependent dose, but not
exceeding one pill per day. This regimen was selected based
on primate challenge data described above, which suggested
that having steady state drug levels in addition to dosing soon
after exposure was important for protection [18].
This study was conducted and completed before the release
of any PrEP efficacy studies referenced above. A parallel study
with  the  same  design  was  conducted  in  Kenyan  MSM  and
female  sex  workers  (FSW)  and  results  published  elsewhere
[19].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
The  study  was  conducted  at  the  MRC/UVRI  Uganda
Research  Unit  on  AIDS’  Masaka  site  in  South  Western
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prospective cohort from which volunteers were recruited for this
study. In this cohort, every 3 months, volunteers were provided
with a comprehensive HIV prevention package including couple
HIV/STI  testing,  and  risk  reduction  counseling,  male  and
female condoms, treatment of STIs, referral for adult medical
male  circumcision  and  for  ART  initiation  when  indicated  per
Ugandan  national  guidelines.  Eligible  HIV-uninfected
volunteers were healthy adults aged 18-49 years in cohabiting
HIV  serodiscordant  relationships  who  had  reported  any
episodes of unprotected vaginal sex with their partner in the
past  3  months  and  the  infected  partner  not  using  ART.
Volunteers with chronic hepatitis B infection (HBsAg-positive)
or with creatinine clearance <80mL/min or pregnant or lactating
mothers  were  excluded  from  the  study  due  to  possible  drug
toxicity  concerns.  Women  of  childbearing  potential  were
required to use a non-barrier form of contraception (hormonal
contraception  or  intrauterine  device)  during  the  study.  In
addition, condoms were provided to all volunteers for protection
against HIV and STIs. Both partners in the HIV serodiscordant
couple were enrolled in the study, but only the HIV-uninfected
partner  was  randomized  to  receive  study  drug.  After
randomization,  volunteers  would  be  discontinued  from  study
medication  if  creatinine  clearance  was  ≤  50mL/min  by
Cockcroft-Gault formula.
Community stakeholder consultations
The  site  conducts  regular  community  stakeholder
consultations on new and ongoing research and has an active
community advisory board (CAB). The CAB reviewed the study
aims  and  patient  information  materials  for  the  protocol  and
provided feedback on potential community concerns.
Ethics
Both members of the couple were aware of each other’s HIV
status and gave written informed consent to participate in the
study.  The  study  was  approved  by  Uganda  Virus  Research
Institute Science and Ethics Committee (UVRI-SEC), Uganda
National Council for Science and Technology (UNCST) and the
National Drug Authority (NDA).
Objectives
The objectives of the study were (1) to evaluate the safety of
daily and intermittent dosing of TDF/FTC; (2) to compare the
acceptability  of  and  adherence  to  daily  and  intermittent
regimens;  (3)  to  evaluate  changes  in  HIV-associated  risk
behaviour; (4) to evaluate HIV-specific immune responses in
volunteers randomized to TDF/FTC and placebo.
Outcomes
The  main  outcome  measures  were:  (1)  clinical  adverse
events  including  mild,  moderate  and  greater  severity  renal
toxicities and serious adverse events (2), adherence rates to
daily and intermittent dosing (3), willingness to use the study
regimen, if shown to be effective (4) change in HIV-associated
risk  behaviour  during  trial  participation  (5),  the  proportion  of
volunteers with HIV-specific immune responses as measured
by interferon-γ ELISpot.
Study procedures
Volunteers were randomized to daily TDF/FTC or placebo, or
intermittent  (fixed  dose  on  Mondays,  Fridays  and  post-coital
dose within 2 hours after sex, not to exceed 1 dose per day)
TDF/FTC  or  placebo  in  a  2:1:2:1  ratio,  and  were  followed
monthly  with  standardized  adherence  and  HIV  risk  reduction
counseling,  HIV  testing,  and  safety  evaluation  for  4  months.
HIV  risk  reduction  strategies  included  provision  of  male  and
female condoms, treatment of STIs, referral for adult medical
male  circumcision  and  for  ART  initiation  when  indicated  per
Ugandan  national  guidelines.  STI  testing  was  conducted  at
screening  and  thereafter  whenever  infection  was  suspected.
The primary measure of adherence was the medication event
monitoring  system  (MEMS;  Aardex,  Switzerland),  in  which  a
microchip  in  the  cap  covering  the  pill  bottle  electronically
recorded every time the bottle was opened and closed. Data
were uploaded monthly. Adherence was also assessed using
monthly self-report per a timeline followback calendar [20-22].
In  brief,  the  calendar  is  used  to  prompt  recall  of  recent
behaviour and has been used successfully in other behavioural
studies  (e.g.  alcohol  use).  Self-report  of  openings  without
removing pills (“curiosity openings”) and of removing multiple
pills  at  one  opening  (“pocket  doses”)  were  collected  each
month.  Sexual  activity  data  were  collected  via  daily  short
message  service  (SMS)  text  message  queries  as  well  as
through  the  timeline  followback  face-to-face  risk  assessment
with a one-month recall period (collected concurrently with the
adherence data). SMS queries prompted volunteers to enter a
password and then asked in the volunteers preferred language,
‘Did you have vaginal sex with your main partner in the last 24
hours?’, ‘Did you use a condom?, ‘Did you have vaginal sex
with any other partner in the last 24 hours?’, ‘Did you use a
condom?’ Volunteers were provided with free mobile phones,
SIM  cards  and  call  credits  for  every  successful  response.
Given the novelty of SMS surveys in collecting adherence data,
post-coital  adherence  was  also  calculated  using  follow-back
self-report data; however, the SMS responses were the primary
measure  of  sexual  activity/behaviour  and  were  used  to
calculate overall intermittent dosing adherence and specifically
post-coital  adherence.  Hematologic  and  biochemical
evaluations  were  performed  monthly.  Full  details  of  the  trial
protocol  can  be  found  in  the  Supplementary  Appendix,
available with the full text of this article at www.plosone.org.
Sample size
Seventy-two volunteers were randomized to active daily and
intermittent  TDF/FTC  regimens  or  respective  placebos  (24
active and 12 placebo recipients per group). Because this was
an  exploratory  study  to  evaluate  safety,  adherence  and
acceptability of intermittent PrEP, it had limited power to rule-
out small differences in safety and adherence. For example,
with 24 volunteers assigned to either daily or intermittent TDF/
FTC,  observing  no  medication-related  serious  toxicity  would
result  in  an  exact,  two  sided  95%  confidence  interval  of
0-14.3%  for  the  corresponding  true  incidence.  Therefore,
Adherence and Acceptability of Intermittent PrEP
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97.5%  confidence  that  the  true  incidence  was  no  more  than
14.3%. With 36 volunteers (combining active and placebo for
each  regimen),  the  study  had  51%  power  to  detect  a  true
adherence rate of 90% for each regimen. Assuming condoms
were used always or frequently (more than half the time) by
60% of volunteers at baseline, the study had >80% power to
detect a 50% decrease in condom usage by treatment group
(n=24).
Randomization and blinding
A random allocation sequence was generated by an external
data  coordinating  center.  The  study  product  was  randomly
assigned to volunteers in mixed blocks of 3 and 6, and dosing
schedules  randomly  assigned  within  study  product  using  a
block  size  of  2.  Investigators  at  the  study  site  enrolled
volunteers  via  an  electronic  enrollment  system,  where
allocation  codes  were  assigned  consecutively  to  eligible
volunteers  at  the  time  of  first  dispensation  of  study  drug.
Allocation to TDF/FTC or identical placebo tablet was blinded
to study volunteers, all research staff and the study sponsor.
Allocation to daily or intermittent dosing was not blinded.
Laboratory methods
Screening and follow-up clinical laboratory safety procedures
were  performed  on-site  following  Good  Clinical  Laboratory
Practices  (GCLP)  in  laboratories  accredited  by  Qualogy,  UK
[23].  Interferon-γ  ELISpots  were  performed  on  frozen
peripheral  blood  mononuclear  cells  (PBMCs)  at  MRC/UVRI
laboratories  and  IAVI  Human  Immunology  Laboratory  on
baseline and follow-up specimens as described previously [24].
A positive ELISpot was defined as (1) an average background
(mock)-subtracted  count  per  peptide  greater  than  38  spot
forming  units  (SFU)  per  106  PBMCs  with  the  coefficient  of
variation no greater than 70%, (2) mean count greater than 4x
mean  background  (mock),  and  (3)  mean  background  (mock)
below 50 SFU/106 PBMCs.
Statistical methods and adherence calculations
Comparisons  of  categorical  and  continuous  variables  were
conducted  using  Fisher’s  exact  test  and  Wilcoxon  rank-sum
test, respectively. A two-sided p-value of less than 0.05 was
considered  to  indicate  statistical  significance.  Statistical
analyses were performed with the use of SAS software, version
9.2 (SAS Institute, Cary, NC, USA). The following adherence
definitions were used:
Primary analyses
Unadjusted  monthly  MEMS  adherence  for  the  daily
group.  The number of MEMS events in 28 days was divided
by 28 days.
Adjusted  monthly  MEMS  adherence  for  the  daily
group.  The number of curiosity openings was subtracted from
the  number  of  MEMS  openings,  while  the  number  of  pocket
doses was added to the number of MEMS openings. Estimates
were calculated over a 28-day interval.
Unadjusted  monthly  MEMS  adherence  for  the
intermittent group.  The sum of days when volunteers were
adherent to fixed dosing (Mondays and Fridays with a MEMS
event,  and  non-Mondays  and  non-Fridays  on  which  neither
sexual  activity  nor  a  MEMS  event  occurred)  plus  post-coital
dosing (other days on which sexual activity was reported by
SMS and a MEMS event occurred), divided by 28.
Adherence to fixed doses.  The number of MEMS events
on Mondays and Fridays in a 28-day interval was divided by 8
days.
Adherence  to  post-coital  doses.    The  number  of  MEMS
events on sexual event days in a 28-day interval was divided
by the number of sexual event days per SMS.
Adherence  to  post-coital  doses  within  2  hours  of
sex.  The number of days of post-coital dosing within 2 hours
of sex by timeline followback report divided by the number of
days with sexual events per SMS.
Secondary analyses
Adjusted  monthly  MEMS  adherence  for  post-coital
dosing  in  the  intermittent  group.    Intermittent  dosing  was
adjusted for extra pills taken out, with all pills assigned to post-
coital dosing.
Alternate definitions of post-coital dosing.  Because SMS
response  rates  varied  (see  below),  adherence  to  post-coital
doses was also calculated as the number of MEMS events on
days with timeline followback reported sexual events divided by
the  number  of  days  with  timeline  followback  reported  sexual
events. Adherence to post-coital doses within 2 hours of sex
was also calculated as the number of days on which post-coital
dosing occurred within 2 hours of sex by timeline followback
report divided by the number of days on which sexual events
occurred by timeline followback report.
Acceptability of PrEP was assessed by a 4-value Likert scale
after 16 weeks in the study. Volunteers with missing responses
for  acceptability  questions  were  excluded  from  the
denominator.
Results
Participant flow
A total of 133 HIV serodiscordant couples were screened, of
which  72  (36  HIV-uninfected  males  and  36  HIV-uninfected
females)  were  enrolled  and  randomized  into  the  study  from
October  2009  through  March  2010.  Sixty-eight  volunteers
(94%)  completed  the  study  (Figure  S1).  Having  abnormal
laboratory  parameters  was  the  commonest  reason  for  study
ineligibility, 34/61 (56%). Among those ineligible for enrollment
due  to  baseline  laboratory  abnormalities  (n=34),  creatinine
clearance  of  <80mL/min  by  Cockcroft-Gault  formula  and
proteinuria on urine dipstick were the most common (77% and
18% respectively). The other major category for exclusion was
study  being  fully  enrolled  by  the  time  lab  results  needed  for
verification of volunteer eligibility became available (n=16). The
trial  ended  when  the  last  enrolled  volunteer  completed  the
study follow-up schedule.
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Baseline  demographic  and  HIV  risk  characteristics  were
similar among the groups (Table 1). 83% of volunteers had 1
sex partner and the remaining 17% had > 1 sex partner in the
past month prior to enrollment. Fifty seven volunteers (79%)
reported always using a condom with the HIV-infected partner.
Alcohol  use  before  sex  and  use  of  street  drugs  were
uncommon.
Participants analyzed
Analysis for safety, adherence, acceptability, and change in
risk  behaviour  included  all  randomized  volunteers  who  were
HIV-1  negative  at  the  time  of  randomization  and  for  whom
study medication was dispensed.
Table 1. Baseline demographics and HIV risk factors for the
past  28  days  by  treatment  assignment  and  treatment
schedule.
  Treatment  
  Active Placebo  
Variable
Daily(24)
n(%)
Intermittent(24)
n(%)
Daily(12)
n(%)
Intermittent(12)
n(%)
Total(72)
N(%)
Male gender 12 (50) 13 (54) 4 (33) 7 (58) 36 (50)
Age – yr
(mean
(range))
33
(20-47)
33 (22-48)
33
(26-47)
33 (27-46) 33 (20-48)
Drank
alcohol
before sex
2 (8) 2 (8) 2 (17) 0 6 (8)
Used any
street drugs
1 (2) 0 (0) 1 (3) 0 (0) 1 (1)
Genital sore
or
discharge
2 (8) 1 (4) 3 (25) 2 (17) 8 (11)
Number of sex
partners past month
       
1 23 (96) 17 (71)
12
(100)
8 (67) 60 (83)
2 1 (4) 6 (25) 0 4 (33) 11 (15)
3 0 1 (4) 0 0 1 (1)
Number of HIV-infected partners past
month
     
0 0 0 0 1 (8) 1 (1)
1 24 (100) 23 (96)
12
(100)
11 (92) 70 (97)
2 0 1 (4) 0 0 1 (1)
Condom use with HIV-
infected partners
       
Not
Applicable
0 0 0 1 (8) 1 (1)
Never 1 (4) 0 0 0 1 (1)
Sometimes 3 (13) 2 (8) 1 (8) 1 (8) 7 (10)
Frequently 1 (4) 4 (17) 1 (8) 0 6 (8)
Always 19 (79) 18 (75) 10 (83) 10 (83) 57 (79)
doi: 10.1371/journal.pone.0074314.t001
Outcomes and estimation
Safety.    Ninety-nine  percent  (227/228)  of  the  non-serious
adverse events (AE) were mild or moderate, with 214 (94%)
judged  unlikely  related  or  not  related  to  study  drug.  The
proportion of volunteers with moderate or above AEs did not
differ  significantly  by  regimen  (daily:  50%,  intermittent:  53%,
p=1.00),  or  treatment  groups  (active:  44%,  placebo:  67%,
p=0.08). The proportion with mild or above AEs was also not
different by regimen or treatment group (Table 2).
The  percentage  of  volunteers  with  gastrointestinal
complaints was not significantly higher in the active treatment
group  (33%)  than  the  placebo  group  (29%)  (p=0.79).  Two
volunteers on active regimen had elevated serum creatinine,
one  mild  (1.1-1.3  times  the  upper  limit  of  normal)  and  one
moderate  (1.4-1.8  times  the  upper  limit  of  normal),  which
resolved  spontaneously  while  continuing  study  medication.
Seven cases of reduced creatinine clearance occurred; five in
active  and  two  in  placebo  recipients,  all  of  which  resolved
spontaneously  without  interruption  of  study  medication.  No
other renal dysfunction was found. One placebo recipient had
an isolated neutropenia, graded as very severe, which resolved
spontaneously  and  did  not  require  discontinuation  of  study
medication. There were no drug-related serious adverse events
(SAEs)  and  no  HIV  infections  detected.  Three  pregnancies
occurred  resulting  in  one  normal  live  birth  (daily  placebo
group),  one  spontaneous  abortion  at  6  weeks  of  pregnancy
(daily  active  group),  and  a  molar  pregnancy  (intermittent
placebo  group)  which  was  treated  and  resolved  without
sequela.
Adherence.    There  was  no  difference  in  adherence  rates
between active and placebo groups, thus these 2 groups were
combined  for  the  adherence  analyses  (Table  3).  Median
unadjusted  MEMS  adherence  rates  were  97%  [IQR:  92-100]
for  daily  dosing  and  91%  [IQR:  73-97]  for  fixed  intermittent
dosing  (p=0.02),  while  adherence  to  any  post-coital  doses
based on sexual events per SMS reporting was much lower
than  the  previous  two  rates:  45%  [IQR:  20-63]  (p<.0001).
Adherence  rates  did  not  differ  by  gender.  MEMS  adherence
rates  did  not  change  when  adjusted  for  curiosity  openings
when  no  pills  were  taken  out  or  when  adjusted  for  extra
openings  and  extra  pills  taken  out.  In  a  post-hoc  analysis,
intermittent  dosing  was  adjusted  for  extra  pills  taken  out,  as
Table  2.  Number  (percentage)  of  volunteers  with  AEs
categorized  by  maximum  severity  experienced,  and
treatment assignment and schedule.
Assignment Schedule Maximum AE Severity
    None Mild Moderate Severe Very Severe
Active Daily 2 (8) 12 (50) 10 (42) 0 (0) 0 (0)
  Intermittent 1 (4) 12 (50) 11 (46) 0 (0) 0 (0)
  Overall 3 (6) 24 (50) 21 (44) 0 (0) 0 (0)
Placebo Daily 0 (0) 4 (33) 8 (67) 0 (0) 0 (0)
  Intermittent 1 (8) 2 (17) 8 (67) 0 (0) 1 (8)
  Overall 1 (4) 6 (25) 16 (67) 0 (0) 1 (4)
doi: 10.1371/journal.pone.0074314.t002
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(which may or may not have been the case). Median MEMS
adherence rate for post-coital dosing did not change after this
adjustment 46% [IQR: 23-67]. The median number of days per
week  of  PrEP  use  according  to  MEMS  data  was  6.8  [IQR
6.5-7.0]  in  the  daily  group  and  2.8  [IQR  2.3-3.3]  in  the
intermittent  group.  Three  volunteers  required  replacement  of
MEMS caps due to loss or damage during the study; no data
was lost.
SMS  response  rates  and  sexual  activity.    The  median
daily SMS response rate was 74% (range, 0-95), increasing to
80% (range, 0-100) when days with major SMS server outages
(>2  hour  of  network  outage  per  day)  were  excluded.  Major
server outages occurred on 8/251 (3.2%) days. Loss of mobile
phones was rare with only 2 phones reported as lost during the
study.  The  median  number  of  days  per  week  when  sex
occurred by SMS reporting was 1.4 (IQR: 1.0-1.9) in the daily
group and 1.6 (IQR: 0.8-2.4) in the intermittent group, and by
timeline followback interview it was 1.7 (IQR: 1.0-2.3) and 1.7
(IQR:  0.9-2.4)  respectively.  In  secondary  analyses  in  which
MEMS adherence was combined with timeline followback data
for sexual activity, the median MEMS adherence rate for post-
coital dosing was 37% (IQR: 25-56) (Table 3). Using timeline
followback adherence with SMS for reporting of sexual activity
data, adherence for post-coital doses within 2 hours of sex was
101% [IQR: 67-129]. Using timeline followback data for both
adherence and sexual activity data, adherence rate was 100%
[IQR: 93-100].
The  most  common  reasons  cited  for  missing  a  pill  dose
were: volunteers not having pills with them (6%), being away
from home (5%), and forgetting to take pill (5%). There were no
differences in reasons for missing a pill dose between daily and
intermittent groups. All volunteers denied sharing pills.
Acceptability.    Ninety-nine  percent  (71/72)  of  participants
would be willing to use the pill regimen most or all of the time if
it  was  shown  to  be  safe,  effective  and  inexpensive  or  free.
There  was  no  difference  in  acceptability  between  daily  and
intermittent  groups  (100%  vs.  97%),  or  between  active  and
placebo groups (100% vs. 96%). MEMS acceptability was high
with 98% (71/72) reporting it was somewhat or very easy to
use.
HIV  behavior  change.    The  median  number  of  sexual
partners in the past month remained at 1 [IQR: 1-1] during the
trial. No other HIV risk behaviors reported at baseline changed
during the trial (data not shown).
HIV-specific  immune  responses.    Minimal  HIV-specific
immune  responses  were  detected  by  IFN-γ  ELISPOT  at
baseline; one of 58 (1.7%) volunteers with specimens available
for ELISPOT testing had a positive IFN-γ ELISPOT response at
baseline, to an Env peptide pool. Three of 50 (6.0%) volunteers
with  post-baseline  ELISPOT  data  had  a  response  to  one  or
more peptides at a single time point. One volunteer each in the
daily and intermittent active treatment groups responded to an
Table 3. PrEP adherence rates for daily and intermittent groups.
ADHERENCE GROUP Adherence parameter Active Placebo P-valueOverall
DAILY ADHERENCE RATE Median
% [IQR]
Overall unadjusted 98 [89-100] 96 [95-99] 0.87 97 [92-100]
  Adjusted1 98 [92-100] 98 [95-99] 0.88 98 [93-100]
INTERMITTENT ADHERENCE RATE
Median % [IQR]
Overall2 80 [74-86] 78 [67-86] 0.60 80 [73-86]
  Fixed doses 91 [78-102] 88 [69-94] 0.25 91 [73-97]
  Post-coital doses (MEMS events and sexual events per SMS)3 40 [23-58] 53 [15-79] 0.45 45 [20-63]
 
Post-coital doses- (MEMS events and timeline follow back self-report sexual
events)
4 39 [29-56] 31 [21-59] 0.58 37 [25-56]
 
Post-coital doses within 2hrs (timeline followback self report and sexual events
per SMS)5
110 [67-129] 93 [68-113] 0.55 101 [67-129]
 
Post-coital doses within 2 hrs (self-report of doses and sexual events per
timeline follow-back calendar)6
100 [94-100] 100 [85-100] 0.46 100 [93-100]
1 Adjusted monthly MEMS adherence for the daily group was calculated as the number of curiosity openings was subtracted from the number of MEMS openings, while the
number of pocket doses was added to the number of MEMS openings, divided by 28.
2 Unadjusted monthly MEMS adherence for the intermittent group was calculated as the sum of days when volunteers were adherent to fixed dosing (Mondays and Fridays
with a MEMS event, and non-Mondays and non-Fridays on which neither sexual activity nor a MEMS event occurred) plus post-coital dosing (other days on which sexual
activity was reported by SMS and a MEMS event occurred), divided by 28
3 Adherence to post-coital doses calculated as number of MEMS events on sexual event days in a 28-day interval divided by the number of sexual event days per SMS.
4 Adherence to post-coital doses calculated as the number of MEMS events on days with timeline followback reported sexual events divided by the number of days with
timeline followback reported sexual events.
5 Adherence to post-coital doses within 2 hours of sex calculated as the number of days of post-coital dosing within 2 hours of sex by timeline followback report divided by
the number of days with sexual events per SMS.
6 Adherence to post-coital doses within 2 hours of sex calculated as the number of days on which post-coital dosing occurred within 2 hours of sex by timeline followback
report divided by the number of days on which sexual events occurred by timeline followback report.
doi: 10.1371/journal.pone.0074314.t003
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daily  placebo  treatment  group  had  positive  IFN-γ  ELISPOT
responses  to  all  pools  at  week  16.  The  IFN-γ  ELISPOT
responses were generally low magnitude.
Discussion
In  this  study  of  both  daily  and  intermittent  PrEP  regimens
among  HIV  serodiscordant  couples,  intermittent  PrEP  was
found to be acceptable and safe. Adherence to daily and fixed
intermittent  dosing  was  high,  but  significantly  lower  for  post-
coital dosing. To our knowledge, this is the first study to report
on safety, adherence and acceptability of an intermittent oral
PrEP  regimen  among  heterosexual  HIV  serodiscordant
couples.
Both  intermittent  and  daily  PrEP  regimens  were  well
tolerated, with a similar proportion of volunteers reporting mild
and  moderate  adverse  events  in  each  regimen  group.  This
observation is in agreement with reports from other larger oral
daily  PrEP  studies  [7,9,10,12,25,26].  There  were  similar
proportions  of  volunteers  with  gastrointestinal  complaints
among active and placebo, and between daily and intermittent
groups  in  the  study.  This  differed  from  the  iPrEx  study  that
reported more frequent moderate (grade 2 and above) nausea
and  unintentional  weight  loss  in  the  active  group  [7].  This
difference could have been due to a shorter follow-up period
and  fewer  volunteers  involved  in  the  current  study.  A  few
volunteers  in  the  active  group  had  self-limited  elevated
creatinine (mild to moderate), and several volunteers in both
active and placebo groups had reduced creatinine clearance.
This  finding  was  similar  to  reports  from  other  PrEP  trials
[7,9,26].
Median adherence rate as measured by MEMS for daily use
was  significantly  higher  than  that  for  fixed  doses  within  the
intermittent regimen; whereas adherence to coitally-dependant
dosing  was  considerably  worse.  Despite  the  statistical
difference between daily and intermittent fixed arm, adherence
rate  was  in  the  90’s  for  each.  There  was  no  change  in
adherence  after  adjusting  for  reported  curiosity  openings  or
pocket doses. Based on MEMS data, volunteers in the daily
group took the pill on almost every day of the week. This high
adherence  is  similar  to  that  reported  in  Partners  PrEP  trial
(92-99% as measured by clinic-based pill counts, unannounced
pill counts and MEMS) [27] – (Haberer in press) and higher
than that reported in iPrEx (89-95% by clinic count and self-
report) [7]. In contrast, adherence to both the daily and fixed
component in the same intermittent regimen was lower among
MSM  and  FSW  in  a  parallel  trial  in  Kenya.  Median  MEMS
adherence rates were 83% (IQR: 63-92) for daily dosing and
55% (IQR: 28-78) for fixed intermittent dosing, while adherence
to any post-coital doses was 26% [IQR: 14-50] [19]. The higher
adherence in the current study may be due to providing PrEP
in the context of stable, socially supported relationships as well
as  the  uninfected  partner’s  hope  of  maintaining  good  health
while  at  the  same  time  preserving  their  serodiscordant
relationship, as proposed within the Partners PrEP study [28].
These  factors  may  be  less  likely  to  play  a  role  in  the  MSM
population studied in the Kenyan trial [29].
Intermittent  fixed  dosing,  at  least  in  this  discordant  couple
population,  appears  to  have  comparable  adherence  to  daily
dosing,  suggesting  that  intermittent  PrEP  regimens  may  be
feasible in certain populations. However, the number of doses
per week necessary for >90% efficacy is likely to be greater
than the 2 doses evaluated in this study. Using data from the
iPrEx study, pharmacokinetic modeling suggested 97% efficacy
for 4 doses per week, which dropped to 76% with 2 doses per
week  [8].  These  data,  derived  from  protection  against  HIV
infection in MSM, may not be readily applicable to heterosexual
transmission. Comparable data on efficacy of less than daily
dosing for heterosexual transmission are not available yet, but
are anticipated from the Partners PrEP study.
Median post-coital adherence as measured by MEMS was
low at 45%. Post-coital dosing among MSM and FSW in the
Kenyan study was even lower at 26% [19]. These findings are
consistent with the incomplete adherence observed with a pre-
and  post-coital  dosing  strategy  for  vaginally  administered
tenofovir microbicide gel in the CAPRISA 004 microbicide trial.
In that study, which observed a 39% reduction in HIV incidence
in  the  tenofovir  group  compared  to  the  placebo  group,  the
median  adherence  was  60%,  and  42%  of  the  women  were
classified as having <50% adherence to two doses of gel for
self-reported sex acts in the last 30 days [30]. The low post-
coital adherence in the current study could have been due to
behavior  and/or  measurement  error.  It  may  be  easier  to
remember to take pills daily, because a routine behaviour is
established.  Unfamiliarity  with  use  of  SMS  to  collect  sexual
behaviour  data  coupled  with  technical  difficulties  (network
outages and a user interface with multiple questions) may have
affected  post-coital  adherence  monitoring  even  though  the
technology  appeared  to  be  relatively  well  accepted  by  study
volunteers.  Quantitative  data  collected  such  as  reasons  for
missed pills, travel away from home and pill sharing did not
explain  why  post-coital  dosing  adherence  was  lower.
Qualitative  data  from  a  parallel  trial  of  daily  and  intermittent
PrEP among MSM and FSW in Kenya identified several factors
influencing  post-coital  dosing  adherence:  alcohol  use  around
the time of sex, moving locations frequently and transactional
sex work [28].
Qualitative data collected during focus group and individual
interviews in the present trial may be informative and are being
prepared for publication.
Measurement  of  adherence  is  challenging  with  self-report
often  providing  overestimates  when  compared  to  objective
measures, such as electronic monitoring, unannounced home-
based pill counts and random drug levels [31-36]. Indeed in this
study, adherence to post-coital dosing as measured by the self
report calendar and SMS report of sexual events alone (without
MEMS)  was  very  high  in  comparison  with  MEMS.  MEMS
adherence, however, is also limited by the fact that it records
bottle  opening  rather  than  actual  medication  use.  Therefore,
the low rate of post-coital pill use as measured by MEMS in this
study could reflect low adherence to PrEP or the inaccuracy of
the methods used to measure it. Other PrEP trials have also
found  discrepancies  between  conventional  methods  such  as
self-report and biologic measures [7,34]. Adherence rate in the
iPrEx trial as measured by clinic pill count and self report was
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volunteers  were  actually  swallowing  the  pills.  Subsequent
analyses found low levels of drug detection, with only 18% of
volunteers  with  drug  levels  reflective  of  daily  use  [37].  In
addition, self-report and clinic pill counts were poorly predictive
of drug exposure [36].
Testing  for  drug  levels  was  included  in  this  study  and  the
findings will be published when available. Participants’ actual
use of trial interventions is often considerably lower than their
reported use hence, raising the issue of social desirability. Low
adherence  is  likely  to  compromise  potential  efficacy  of  the
intervention and may make interpretation of trial data difficult;
since  intent-to-treat  efficacy  and  as-treated  efficacy  will  be
different. Low adherence may also limit detection of adverse
events therefore, misrepresenting safety concerns.
The main reasons given for missing pills were volunteers not
having pills with them while away from home and forgetfulness,
and these reasons were similar for both daily and intermittent
regimen groups. These reasons are similar to those cited in a
phase 2 oral PrEP trial conducted in West Africa [38].
Acceptability of oral PrEP was high with 99% of participants
reporting willingness to use the pills most of the time or all the
time if PrEP was shown to be safe, effective, inexpensive or
free. There was no significant difference between those willing
to use intermittent (97%) and daily regimens (100%).
There was no change in HIV sexual risk behaviour during the
study. Although it is theoretically possible that individuals may
feel protected and abandon condom use and other protective
measures, none of the oral or topical PrEP trials to date have
observed increased HIV risk behavior that would suggest risk
compensation  [7,9,10,14,30].  Despite  encouraging  data  from
animal studies, we found no evidence of HIV-specific immune
responses  as  measured  by  a  validated  IFN-γ  ELISPOT  in
volunteers on PrEP It is possible that a longer duration of PrEP
and/or  more  intensive  mucosal  exposures  are  necessary  to
develop  these  responses,  or  that  too  few  volunteers  were
exposed  to  HIV  in  this  trial.  Alternatively,  if  PrEP-related
protective  responses  do  exist,  they  may  be  located  in  the
mucosa  and  may  not  be  evaluable  with  T-cell  assays  in
PBMCs such as IFN-γ ELISPOTs.
Summary
Our study demonstrated that FTC/TDF was safe when taken
either daily or intermittently for HIV pre-exposure prophylaxis
by HIV-uninfected volunteers living in coupled serodiscordant
relationships.  Adherence  was  high  to  both  daily  and  fixed
intermittent dosing, but not for coitally-dependent dosing, the
measurement of which may have been imperfect. These data,
together with findings from the Kenyan intermittent PrEP trial
[19], suggest that post-coital dosing adherence will be difficult
to  measure  accurately.  If  the  low  post-coital  adherence
observed in these two studies is accurate, post-coital dosing is
unlikely to be effective in these populations.
The  study  was  limited  by  the  short  follow-up  period  and
relatively  small  number  of  volunteers  which  hamper
generalizability of results. Volunteers with creatinine clearance
<80  ml/min  were  not  eligible  for  enrollment.  Seventy-three
percent  of  ineligible  volunteers  were  excluded  for  lab
abnormalities, with creatinine clearance <80 ml/min accounting
for 43% of these exclusions. The percentage of all screened
volunteers  who  were  excluded  due  to  decreased  creatinine
clearance was 20%; this may limit the generalizability of the
results  in  part  to  populations  with  high  creatinine  clearance.
Study volunteers were blinded to their active drug or placebo
assignment and at the time of conduct of the study, PrEP had
not yet been shown to be effective. Adherence, acceptability,
risk  compensation  behavior  and  other  outcomes  may  differ
when PrEP which is known to be effective is available in the
community. Volunteers were recruited from a pre-existing HIV
serodiscordant  couple  cohort  in  which  participants  received
regular couple and individual HIV risk reduction counseling and
other  preventive  measures.  Consistent  HIV  testing  and
counseling offered during HIV biomedical intervention studies
has been perceived by volunteers to affect their risk behaviour
in a positive way, by giving them knowledge and awareness of
their HIV-negative status, hence added motivation to negotiate
and  use  condoms  more  regularly  [39].  Therefore,  their
behaviour may not reflect that of the general population.
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